3/18/2024

Levetiracetam Injection

Products Affected - Description

- Levetiracetam injection, Hikma, 100 mg/mL, 5 mL vial, 25 count, NDC 00143-9673-25
- Levetiracetam injection, WG Critical Care, 5 mg/mL, 50 mL premixed bag, 10 count, NDC 44567-0500-10 - discontinued

Reason for the Shortage

- Armas has levetiracetam injection available.
- Athenex is no longer supplying product.
- Dr. Reddy's did not provide a reason for the shortage.
- Eugia has levetiracetam injection available.
- Fresenius Kabi has levetiracetam injection available.
- Hikma did not provide a reason for the shortage.
- Mylan has levetiracetam injection available.
- Pfizer has levetiracetam injection available.
- Sagent has levetiracetam injection available.
- Sun Pharma is not manufacturing levetiracetam injection at this time.
- UCB has product available.
- WG Critical Care has levetiracetam injection in premixed bags available. The 50 mL premixes were discontinued in early-2024.
- X-Gen discontinued levetiracetam in 2022.

Available Products

- Keppra injection, UCB, 100 mg/mL, 5 mL vial, 10 count, NDC 50474-0002-63
- Levetiracetam injection, Armas Pharmaceuticals, 100 mg/mL, 5 mL vial, 10 count, NDC 72485-0106-10
- Levetiracetam injection, Armas Pharmaceuticals, 100 mg/mL, 5 mL vial, 25 count, NDC 72485-0106-25
- Levetiracetam injection, Dr. Reddy's, 10 mg/mL, 100 mL premixed bag, 10 count, NDC 43598-0636-10
- Levetiracetam injection, Dr. Reddy's, 15 mg/mL, 100 mL premixed bag, 10 count, NDC 43598-0637-10
- Levetiracetam injection, Dr. Reddy's, 5 mg/mL, 100 mL premixed bag, 10 count, NDC 43598-0635-10
- Levetiracetam injection, Eugia US, 10 mg/mL, 100 mL premixed bag, 10 count, NDC 55150-0247-47
- Levetiracetam injection, Eugia US, 100 mg/mL, 5 mL vial, 10 count, NDC 55150-0177-05
- Levetiracetam injection, Eugia US, 15 mg/mL, 100 mL premixed bag, 10 count, NDC 55150-0248-47
- Levetiracetam injection, Eugia US, 5 mg/mL, 100 mL premixed bag, 10 count, NDC 55150-0246-47
- Levetiracetam injection, Fresenius Kabi, 100 mg/mL, 5 mL vial, 10 count, NDC 63323-0400-05
- Levetiracetam injection, Mylan (Viatris), 10 mg/mL, 100 mL premixed bag, 10 count, NDC 67457-0265-10
- Levetiracetam injection, Mylan (Viatris), 15 mg/mL, 100 mL premixed bag, 10 count, NDC 67457-0266-10
- Levetiracetam injection, Mylan (Viatris), 5 mg/mL, 100 mL premixed bag, 10 count, NDC 67457-0255-10
- Levetiracetam injection, Pfizer, 100 mg/mL, 5 mL vial, 25 count, NDC 00409-1886-02
- Levetiracetam injection, Sagent, 100 mg/mL, 5 mL vial, 10 count, NDC 25021-0780-05
- Levetiracetam injection, WG Critical Care, 10 mg/mL, 100 mL premixed bag, 10 count, NDC 44567-0502-10
- Levetiracetam injection, WG Critical Care, 15 mg/mL, 100 mL premixed bag, 10 count, NDC 44567-0503-10
- Levetiracetam injection, WG Critical Care, 5 mg/mL, 100 mL premixed bag, 10 count, NDC 44567-0501-10

Estimated Resupply Dates

- Hikma has levetiracetam 100 mg/mL 5 mL vials on back order and the company estimates a release date of late-March 2024.

Updated

Updated March 18, 2024 by Michelle Wheeler, PharmD, Drug Information Specialist. Created May 14, 2015 by Jane Chandramouli, PharmD, Drug Information Specialist. © 2024, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.